# US 6,727,229 B2 · 11,12-substituted lactone ketolide derivatives having antibacterial activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,229 B2
- Document ID: US6727229B2
- Status: Granted
- Kind: B2
- Application number: 10/223,144
- Filed: 2002-08-19
- Published: 2004-02-26
- Granted: 2004-04-27
- Earliest claimed: 2002-08-19
- Assignees: Enanta Pharmaceuticals, Inc.
- Inventors: Nha Huu Vo; Ly Tam Phan; Ying Hou; Tongzhu Liu; Yat Sun Or
- Web page: https://patentgrep.com/patent/US6727229B2

## CPC

- C07H 17/08: Hetero rings containing eight or more ring members, e.g. erythromycins
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Novel 11-12 substituted lactone ketolide derivatives and pharmaceutically-acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically-acceptable carrier are described. Also described are a method for treating bacterial infections by administering to an animal a pharmaceutical composition containing a therapeutically effective amount of a compound of the invention and processes for the preparation of such compounds.

## Claims

### Claim 1

A compound represented by the formula
and the pharmaceutically acceptable salts, esters and prodrugs thereof,
wherein
L is selected from the group consisting of:
(1) —CH(OH)CH3;
(2) C1-C6 alkyl, optionally substituted with one or more substituents selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl;
(3) C2-C6 alkenyl, optionally substituted with one or more substituents selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl; and
(4) C2-C6 alkynyl, optionally substituted with one or more substituents selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl;
R1 is selected from the group consisting of C1-C6-alkyl, C2-C6-alkenyl and C2-C6-alkynyl, each optionally substituted with one or more substituents selected from the group consisting of:
(1) halogen;
(2) aryl;
(3) substituted aryl;
(4) heteroaryl;
(5) substituted heteroaryl;
(6) —O—R5, where R5 is selected from the group consisting of:
a. hydrogen;
b. aryl;
c. substituted aryl;
d. heteroaryl; and
e. substituted heteroaryl;
(7) —O—C1-C6-alkyl-R5;
(8) —O—C2-C6-alkenyl-R5;
(9) —O—C2-C6-alkynyl-R5; and
(10) —NR6R7, where R6 and R7 are each independently selected from the group consisting of: hydrogen; C1-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; and C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; or R6R7 taken together with the nitrogen atom to which they are attached form a 3- to 7-membered ring which may optionally contain one or more hetero functions selected from the group consisting of —O—, —NH—, —N(C1-C6-alkyl)-, —N(aryl)-, —N(heteroaryl)-, —S—, —S(O)— and —S(O)2—;
R2 is selected from the group consisting of:
(1) hydrogen;
(2) C1-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of:
a. halogen;
b. aryl;
c. substituted aryl;
d. heterocyclic;
e. substituted heterocyclic;
f. —O—R3, where R3 is selected from the group consisting of:
i. hydrogen;
ii. aryl;
iii. substituted aryl;
iv. heteroaryl; and
v. substituted heteroaryl;
g. —O—C1-C6-alkyl-R3;
h. —O—C2-C6-alkenyl-R3;
i. —O—C2-C6-alkynyl-R3; and
j. —NR6R7;
(3) C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of:
a. halogen;
b. aryl;
c. substituted aryl;
d. heterocyclic;
e. substituted heterocyclic;
f. —O—R3;
g. —O—C1-C6-alkyl-R3;
h. —O—C2-C6-alkenyl-R3;
i. —O—C2-C6-alkynyl-R3; and
j. —NR6R7; and
(4) C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of:
a. halogen;
b. aryl;
c. substituted aryl;
d. heterocyclic;
e. substituted heterocyclic;
f. —O—R3;
g. —O—C1-C6-alkyl-R3;
h. —O—C2-C6-alkenyl-R3;
i. —O—C2-C6-alkynyl-R3; and
j. —NR6R7;
X is O;
Z is selected from the group consisting of:
(1) hydrogen;
(2) halogen; and
(3) methyl; and
Rp is hydrogen or a hydroxy protecting group.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein L is CH2CH3, X is —S—, Z is F, R1 is CH3 and R2 and Rp are as defined in claim 1.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically-acceptable salt, ester or prodrug thereof, in combination with a pharmaceutically acceptable carrier.

### Claim 4 (depends on 3)

A method for controlling a bacterial infection in an animal comprising administering to an animal a therapeutically-effective amount of a pharmaceutical composition according to claim 3.

### Claim 5 (depends on 1)

A process for preparing a compound represented by the formula
wherein Z is halogen and L, X, R1, R2, Rp are as defined in claim 1, the method comprising
(a) treating a compound represented by the formula
wherein L, X, R1, and R2 are as previously defined and Rp is a hydroxy protecting group with a halogenating agent, and optionally deprotecting Rp.

### Claim 6 (depends on 5)

The process of claim 5 wherein said halogenating agent is selected from the group consisting of: N-fluorobenzenesulfonimide in the presence of base; 10% F2 in formic acid; 3,5-dichloro-1-fluoropyridinium tetrafluoroborate; 3,5-dichloro-1-fluoropyridinium triflate; (CF3SO2)2NF; N-fluoro-N-methyl-p-toluenesulfonamide in the presence of base; N-fluoropyridinium triflate; N-fluoroperfluoropiperidine in the presence of base; hexachloroethane in the presence of base; CF3CF2CH2ICl2; SO2Cl2; SOCl2; CF3SO2Cl in the presence of base; Cl2; NaOCl in the presence of acetic acid; Br2/yridine.HBr; Br2/acetic acid; N-bromosuccinimide in the presence of base; LDA/BrCH2CH2Br; LDA/CBr4; and N-Iodosuccinimide in the presence of base; and I2.

### Claim 7 (depends on 1, 5)

The process of claim 5 wherein said halogenating agent is N-fluorobenzenesulfonimide in the presence of sodium hydride and the product is a compound represented by formula I wherein Z is F and L, X, R1 R2 and Rp are as defined in claim 1.
